GlassScriptPhysician profile
Blanca Durand
NPI 1902802689
$2,473.81
in general payments reported to CMS, 2019-2025
14 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.70 · 2020: $1,019 · 2021: $365 · 2022: $163 · 2023: $240 · 2024: $271 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $952.67 | 2020 | |
| Aerin Medical INC. | $306.29 | 2022-2025 | |
| Stryker Corporation | $273.31 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $266.85 | 2022-2025 | Dupixent |
| Genzyme Corporation | $186.91 | 2020-2025 | |
| Glaxosmithkline, LLC. | $184.47 | 2022-2025 | Nucala |
| Optinose US, INC. | $132.24 | 2019-2023 | |
| Intersect Ent, INC. | $46.66 | 2021 | |
| Medtronic, INC. | $40.89 | 2021-2023 | Midas Rex |
| Alk-Abello, INC | $22.14 | 2020 | |
| Covidien LP | $18.20 | 2019 | |
| Merck Sharp & Dohme LLC | $17.08 | 2023 | |
| Hikma Pharmaceuticals USA | $14.64 | 2023 | Ryaltris |
| Smith+Nephew, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blanca Durand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.